Advertisement
Advertisement

PRLD

PRLD logo

Prelude Therapeutics Incorporated

2.17
USD
Sponsored
+0.15
+7.18%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

2.17

0.00
0.00%

PRLD Earnings Reports

Positive Surprise Ratio

PRLD beat 15 of 21 last estimates.

71%

Next Report

Date of Next Report
Mar 09, 2026
Estimate for Q4 25 (Revenue/ EPS)
$35.70M
/
-$0.02
Implied change from Q3 25 (Revenue/ EPS)
+449.23%
/
-92.31%
Implied change from Q4 24 (Revenue/ EPS)
+792.50%
/
-94.74%

Prelude Therapeutics Incorporated earnings per share and revenue

On Nov 12, 2025, PRLD reported earnings of -0.26 USD per share (EPS) for Q3 25, beating the estimate of -0.37 USD, resulting in a 30.22% surprise. Revenue reached 6.50 million, compared to an expected --, with a 0.00% difference. The market reacted with a +8.89% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analysts forecast an EPS of -0.02 USD, with revenue projected to reach 35.70 million USD, implying an decrease of -92.31% EPS, and increase of 449.23% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Prelude Therapeutics Incorporated reported EPS of -$0.26, beating estimates by 30.22%, and revenue of $6.50M, 0% as expectations.
The stock price moved up 8.89%, changed from $1.35 before the earnings release to $1.47 the day after.
The next earning report is scheduled for Mar 09, 2026.
Based on 5 analysts, Prelude Therapeutics Incorporated is expected to report EPS of -$0.02 and revenue of $35.70M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement